Prolia Pricing: A High Bar For Osteoporosis But Room To Tap Oncology Potential
This article was originally published in The Pink Sheet Daily
Executive Summary
With a wholesale acquisition cost of $1,650 a year for Prolia, Amgen has effectively sacrificed the first-line treatment market for osteoporosis in favor of long-term potential in future indications.
You may also be interested in...
Amgen's Prolia Bags Favorable Draft Appraisal From UK Medicines Watchdog
NICE considers denosumab a cost-effective use of NHS resources for second-line osteoporosis use.
Amgen's Prolia Bags Favorable Draft Appraisal From UK Medicines Watchdog
NICE considers denosumab a cost-effective use of NHS resources for second-line osteoporosis use.
FDA Okays Amgen's Prolia, But With Hefty Post-Marketing Requirements In Tow
Denosumab will be indicated for use in postmenopausal women with osteoporosis who are at high risk for fractures.